Avecia allies with Gryphon
Gryphon Sciences, of San Francisco, and Avecia Biotechnology have formed a strategic alliance to develop and supply Gryphon's protein therapeutics.
The alliance combines Gryphon's synthetic protein design technology with Avecia's experience as a large-scale peptide manufacturer. Gryphon has identified a number of chemically synthesised protein therapeutics that have been validated in preclinical models. These drugs are made using native chemical ligation to join peptide segments to form intact proteins. Avecia will manufacture on the scale required to supply late stage clinical trials and launch product needs.